Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting
enzyme in the
nicotinamide adenine dinucleotide (
NAD+) salvage pathway and plays a crucial role in the maintenance of the NAD+ pool during
inflammation. Considering that macrophages are essential for tissue homeostasis and
inflammation, we sought to examine the functional impact of NAMPT in inflammatory macrophages, particularly in the context of
inflammatory bowel disease (IBD). In this study, we show that mice with NAMPT deletion within the myeloid compartment (Namptf/fLysMCre+/-, Nampt mKO) have more pronounced
colitis with lower survival rates, as well as numerous uncleared apoptotic
corpses within the mucosal layer. Nampt-deficient macrophages exhibit reduced phagocytic activity due to insufficient NAD+ abundance, which is required to produce
NADPH for the oxidative burst.
Nicotinamide mononucleotide (NMN) treatment rescues
NADPH levels in Nampt mKO macrophages and sustains
superoxide generation via
NADPH oxidase. Consequently, Nampt mKO mice fail to clear dead cells during tissue repair, leading to substantially prolonged chronic
colitis. Moreover, systemic administration of NMN, to supply
NAD+, effectively suppresses the disease severity of DSS-induced
colitis. Collectively, our findings suggest that activation of the NAMPT-dependent NAD+ biosynthetic pathway, via NMN administration, is a potential therapeutic strategy for managing inflammatory diseases.